The size of the European Diabetic Retinopathy Market has been estimated at USD 1.26 billion in 2019. It is projected to reach USD 1.73 billion by 2024, at a CAGR of 6.55% during the forecast period.
Diabetic retinopathy is a medical condition which damages the retina and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the epidemic at its initial stage.
Growth enhancing factors are government initiatives, abundant R&D activities, and skill set enhancement of healthcare providers. Such supportive initiatives, coupled with rising awareness among patients, are anticipated to result in lucrative growth. Treatment of diabetic retinopathy is expected to gain patients' willingness for treatment by introducing advanced technology and reducing pain by using laser procedure with quick recovery time.
The adoption of sedentary lifestyles and changes in food habits is driving the demand of the market. An increasing number of diabetic patients is also considered to be a significant factor propelling the growth of the Europe diabetic retinopathy market. Growing awareness over the availability of drugs for different diseases is accelerating the demand of the market. The rise in the geriatric population and increasing incidences of blindness due to damage of blood vessels in the retina is gearing up the need of the market. Also, the growing number of surgical treatment procedures is prompting the growth of this market in Europe.
Growth opportunities for the market lie in the emergence of the latest technological developments and the introduction of innovative devices in favour of the end-user. Increasing concern towards health among individuals and the rise in the knowledge over the treatment procedures and also the availability of trained physicians are leveraging the growth of the market. Furthermore, increasing the constructional activities of hospitals with the latest equipment is fueling the demand of the market.
However, fluctuations in the production rate of the devices in the medical sector and the cost of installation and maintenance of the equipment is a bit expensive are slowly hampering the growth of the diabetic retinopathy market. Stringent rules and regulations by the government in approving new products has remained a challenging factor for the market.
Based on Region, the European diabetic retinopathy market holds the highest share in the market, driven by rising patient awareness levels, particularly in the Western European countries. Increasing support from the government through investments is merely magnifying the growth rate of the UK diabetic retinopathy market.
Increasing incidences of obesity and cardiovascular problems in many people due to their lifestyle are lavishing the diabetic retinopathy market in Spain. The rise in the funds from both private and public organizations is gearing up the growth rate in the Spain market.
Ongoing research in the biotechnology field is ascribed to bolster the demand of the German diabetic retinopathy market. Growing priority for laser treatment surgeries is also broadening the need of the market in Germany.
Growing demand for low cost and secure operative surgical procedures is rising the need for diabetic retinopathy in Italy.
People's interest in healthy lifestyles and increasing demand for early diagnosis to have a permanent cure of the diseases is accelerating the diabetic retinopathy market in France enormously.
Leading companies in the Europe Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
This research report has been segmented and sub-segmented into the following categories:
By Treatment Type:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures